Kenvue rebuked claims of a connection between autism and acetaminophen and said it is “deeply concerned with the health risk this poses for expecting mothers.”

Kenvue shares rose 6% in premarket trading on Tuesday, set to rebound from a record low hit in the previous session as U.S. President Donald Trump linked its popular pain medication Tylenol to autism.

The White House is reportedly planning to link Tylenol use during pregnancy to autism. The news pushed Kenvue stock down 8%.

“Don’t take Tylenol,” Trump instructed pregnant women around a dozen times during a White House news conference. He also urged mothers not to give infants the drug, known by the generic name acetaminophen in the U.S. or paracetamol in other countries.

Tylenol, a popular over-the-counter pain reliever whose active ingredient is acetaminophen, is made by Kenvue, a spinoff of Johnson & Johnson. In early spring, the company moved its global headquarters to New Jersey, cutting the ribbon on the new location with Gov. Phil Murphy and then-Kenvue CEO Thibaut Mongon.

Kenvue, a two-year-old spinoff from Johnson & Johnson, is confronting a public-relations nightmare as President Trump and others suggest unproven links between the pain reliever and autism.

Investing.com -- President Donald Trump once again issued a warning on social media against the use of Tylenol during pregnancy and for young children, while also suggesting parents break up standard childhood vaccines into separate shots administered over multiple medical visits.

U.S. President Donald Trump on Friday repeated his call for pregnant women and young children to stop using popular pain medication Tylenol, defying widespread criticism from medical groups, and offered further healthcare advice not backed by science.